Antoine Adenis - Concepedia

Author

Antoine Adenis

Also Known As

A Adenis, A. Adenis, ANTOINE ADENIS, Adenis, Antoine, Antoine ADENIS, Antoine Adenis, Antoine Adenis, Véronique Christophe, Yiping Mou

122

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Centre Oscar Lambret Centre Léon Bérard Institut Gustave Roussy Institut Bergonié Inserm

About

Antoine Adenis is an author at Centre Oscar Lambret specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	1.4K
2	Health Sciences	8	8	312
3	Gastroenterology	6	6	417
4	Hepatology	2	2	116
5	Biostatistics	1	1	30

Antoine Adenis

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart, The Lancet Oncology Investigational AuroraMedicinePharmacologyPathologyBreast Cancer	2015	248
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era Philippe A. Cassier, Elena Fumagalli, Piotr Rutkowski, Clinical Cancer Research	2012	232
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial Aurore Blesius, Philippe A. Cassier, François Bertucci, BMC Cancer	2011	126
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Axel Le Cesne, Jean‐Yves Blay, Binh Bui, European Journal of Cancer Oral Masitinib MesilateSurgical OncologyGastrointestinal OncologyMedicineGastroenterology	2010	123
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial Olivier Mir, Claire Cropet, Maud Toulmonde, The Lancet Oncology Open-label Phase 2Gastrointestinal OncologyMedicineCancer ManagementGastroenterology	2016	120
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial Anna Patrikidou, Sylvie Chabaud, Isabelle Ray‐Coquard, Annals of Oncology Residual DiseaseSurgical OncologyMedicineMetronomic TherapyPhase Iii Trial	2012	101
Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases Nicolas Penel, Jessica Grosjean, Y Robin, Sarcoma	2008	94
Image-Guided Robotic Stereotactic Body Radiation Therapy for Liver Metastases: Is There a Dose Response Relationship? C. Vautravers-Dewas, S. Dewas, F. Bonodeau, International Journal of Radiation OncologyBiologyPhysics Adaptive RadiotherapyRadiation MedicineHepatologyMedical ImagingRadiation Therapy	2011	88
Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting Stéphane Bouchet, Sylvie Poulette, Karine Titier, European Journal of Cancer Gastrointestinal OncologyMedicineCancer ManagementGastroenterologyColorectal Cancer	2016	85
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group Anna Patrikidou, Julien Dômont, Sylvie Chabaud, European Journal of Cancer Gist PatientsMedicineMetronomic TherapyPathologyMolecular Subgroups	2015	82

Page 1